Undue : Actualité Undue en direct - P1 | Bourse Reflex
Accueil > Tags > Undue

  • Toutes les actualités en rapport avec « Undue »

30/06 18:15 Undue - Antalis International - Proposed Offering

03/01 18:00 Undue - Disclosure of the total number of voting rights and shares composing the share capital

03/01 18:00 Undue - SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

13/12 18:30 Undue - GENTICEL REPORTS FINAL RESULTS OF GTL001 PHASE 2 TRIAL IN HPV16/18-INFECTED WOMEN

30/11 08:00 Undue - GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines

27/10 18:35 Undue - BUSINESS UPDATE - THIRD QUARTER 2016

22/09 19:00 Undue - GENTICEL PRESENTS FIRST HALF 2016 FINANCIAL RESULTS AND UPDATES ITS OPERATIONAL OUTLOOK

08/08 18:35 Undue - Disclosure of the total number of voting rights and shares composing the share capital

08/08 18:35 Undue - HALF-YEAR SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

28/07 18:35 Undue - BUSINESS UPDATE - SECOND QUARTER 2016

18/07 16:00 Undue - ZIMMER BIOMET TO ACQUIRE MEDTECH

07/07 19:30 Undue - Disclosure of the total number of voting rights and shares composing the share capital

06/07 18:35 Undue - GENTICEL APPOINTS EUMEDIX AS STRATEGIC ADVISOR TO SUPPORT COMPANY'S ACCESS TO INNOVATIVE DRUG CANDIDATES

23/06 17:45 Undue - GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN

15/06 19:30 Undue - GENTICEL TO PRESENT CLINICAL RESULTS OF GTL001 AND PRECLINICAL RESULTS OF GTL002 AT EUROGIN 2016 CONGRESS IN SALZBURG, AUSTRIA

13/06 18:35 Undue - GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

01/06 19:00 Undue - GENTICEL ANNOUNCES PUBLICATION IN 'CLINICAL CANCER RESEARCH' OF PHASE 1 TRIAL RESULTS SUPPORTING SAFETY, TOLERABILITY AND IMMUNOGENICITY OF GTL001

20/10 14:30 Undue - EasyLink Services to Offer Fax as a Service Integrated Into SAP(R) Business ByDesign(TM)

19/10 16:35 Undue - Apricus Biosciences Announces Issuance of Korean Patent, Expanding Its Patent Portfolio for Its Topical Cream to Treat Premature Ejaculation

14/10 08:30 Undue - Apricus Biosciences Announces New Data Published in the International Journal of Pharmaceutics Confirming Efficiency of NexACT(R) Drug Delivery Technology